Maravai LifeSciences (MRVI) Competitors $4.46 +0.03 (+0.56%) As of 02:47 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MRVI vs. DNTH, LEGN, INDV, NAMS, and KNSAShould you buy Maravai LifeSciences stock or one of its competitors? MarketBeat compares Maravai LifeSciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maravai LifeSciences include Dianthus Therapeutics (DNTH), Legend Biotech (LEGN), Indivior (INDV), NewAmsterdam Pharma (NAMS), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry. MRVI vs. DNTHMRVI vs. LEGNMRVI vs. INDVMRVI vs. NAMSMRVI vs. KNSAHow does Maravai LifeSciences compare to Dianthus Therapeutics?Maravai LifeSciences (NASDAQ:MRVI) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends. Which has more risk and volatility, MRVI or DNTH? Maravai LifeSciences has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Do analysts rate MRVI or DNTH? Maravai LifeSciences presently has a consensus price target of $5.50, suggesting a potential upside of 23.46%. Dianthus Therapeutics has a consensus price target of $117.82, suggesting a potential upside of 30.58%. Given Dianthus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dianthus Therapeutics is more favorable than Maravai LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Dianthus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.00 Is MRVI or DNTH more profitable? Maravai LifeSciences has a net margin of -51.07% compared to Dianthus Therapeutics' net margin of -12,998.50%. Maravai LifeSciences' return on equity of -17.87% beat Dianthus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Maravai LifeSciences-51.07% -17.87% -9.08% Dianthus Therapeutics -12,998.50%-27.30%-25.91% Do institutionals and insiders have more ownership in MRVI or DNTH? 50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher valuation & earnings, MRVI or DNTH? Maravai LifeSciences has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaravai LifeSciences$185.74M6.19-$130.77M-$0.71N/ADianthus Therapeutics$2.04M2,418.08-$162.34M-$4.13N/A Does the media refer more to MRVI or DNTH? In the previous week, Maravai LifeSciences and Maravai LifeSciences both had 3 articles in the media. Maravai LifeSciences' average media sentiment score of 0.48 beat Dianthus Therapeutics' score of 0.25 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dianthus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryMaravai LifeSciences beats Dianthus Therapeutics on 9 of the 16 factors compared between the two stocks.How does Maravai LifeSciences compare to Legend Biotech?Maravai LifeSciences (NASDAQ:MRVI) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation. Do insiders and institutionals have more ownership in MRVI or LEGN? 50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate MRVI or LEGN? Maravai LifeSciences currently has a consensus target price of $5.50, suggesting a potential upside of 23.46%. Legend Biotech has a consensus target price of $59.00, suggesting a potential upside of 107.45%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Legend Biotech is more favorable than Maravai LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Legend Biotech 1 Sell rating(s) 3 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is MRVI or LEGN more profitable? Legend Biotech has a net margin of -21.98% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Maravai LifeSciences-51.07% -17.87% -9.08% Legend Biotech -21.98%-24.92%-14.87% Which has preferable earnings and valuation, MRVI or LEGN? Maravai LifeSciences has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaravai LifeSciences$185.74M6.19-$130.77M-$0.71N/ALegend Biotech$1.14B4.62-$296.80M-$0.68N/A Which has more volatility and risk, MRVI or LEGN? Maravai LifeSciences has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Does the media refer more to MRVI or LEGN? In the previous week, Legend Biotech had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 5 mentions for Legend Biotech and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.48 beat Legend Biotech's score of 0.07 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryMaravai LifeSciences and Legend Biotech tied by winning 8 of the 16 factors compared between the two stocks.How does Maravai LifeSciences compare to Indivior?Maravai LifeSciences (NASDAQ:MRVI) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership. Do analysts prefer MRVI or INDV? Maravai LifeSciences currently has a consensus price target of $5.50, suggesting a potential upside of 23.46%. Indivior has a consensus price target of $39.33, suggesting a potential upside of 4.99%. Given Maravai LifeSciences' higher probable upside, equities analysts clearly believe Maravai LifeSciences is more favorable than Indivior.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Indivior 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of MRVI or INDV? 50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by company insiders. Comparatively, 0.7% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, MRVI or INDV? Maravai LifeSciences has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Indivior has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Is MRVI or INDV more profitable? Indivior has a net margin of 19.44% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Indivior's return on equity.Company Net Margins Return on Equity Return on Assets Maravai LifeSciences-51.07% -17.87% -9.08% Indivior 19.44%-219.26%29.40% Which has preferable valuation and earnings, MRVI or INDV? Indivior has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaravai LifeSciences$185.74M6.19-$130.77M-$0.71N/AIndivior$1.24B3.69$210M$1.9519.21 Does the media refer more to MRVI or INDV? In the previous week, Indivior had 1 more articles in the media than Maravai LifeSciences. MarketBeat recorded 4 mentions for Indivior and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.48 beat Indivior's score of 0.33 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Indivior 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryIndivior beats Maravai LifeSciences on 12 of the 17 factors compared between the two stocks.How does Maravai LifeSciences compare to NewAmsterdam Pharma?NewAmsterdam Pharma (NASDAQ:NAMS) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability. Do institutionals and insiders hold more shares of NAMS or MRVI? 89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, NAMS or MRVI? NewAmsterdam Pharma has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Do analysts rate NAMS or MRVI? NewAmsterdam Pharma currently has a consensus price target of $48.00, indicating a potential upside of 34.28%. Maravai LifeSciences has a consensus price target of $5.50, indicating a potential upside of 23.46%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe NewAmsterdam Pharma is more favorable than Maravai LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83Maravai LifeSciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is NAMS or MRVI more profitable? Maravai LifeSciences has a net margin of -51.07% compared to NewAmsterdam Pharma's net margin of -943.23%. Maravai LifeSciences' return on equity of -17.87% beat NewAmsterdam Pharma's return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam Pharma-943.23% -26.49% -24.37% Maravai LifeSciences -51.07%-17.87%-9.08% Does the media prefer NAMS or MRVI? In the previous week, Maravai LifeSciences had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 3 mentions for Maravai LifeSciences and 1 mentions for NewAmsterdam Pharma. Maravai LifeSciences' average media sentiment score of 0.48 beat NewAmsterdam Pharma's score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maravai LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, NAMS or MRVI? Maravai LifeSciences has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$22.50M185.72-$203.82M-$1.79N/AMaravai LifeSciences$185.74M6.19-$130.77M-$0.71N/A SummaryMaravai LifeSciences beats NewAmsterdam Pharma on 10 of the 17 factors compared between the two stocks.How does Maravai LifeSciences compare to Kiniksa Pharmaceuticals International?Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership. Which has more risk & volatility, KNSA or MRVI? Kiniksa Pharmaceuticals International has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Do analysts recommend KNSA or MRVI? Kiniksa Pharmaceuticals International currently has a consensus target price of $60.86, suggesting a potential upside of 12.18%. Maravai LifeSciences has a consensus target price of $5.50, suggesting a potential upside of 23.46%. Given Maravai LifeSciences' higher possible upside, analysts plainly believe Maravai LifeSciences is more favorable than Kiniksa Pharmaceuticals International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals International 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Maravai LifeSciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has stronger earnings & valuation, KNSA or MRVI? Kiniksa Pharmaceuticals International has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals International$677.56M6.16$59.01M$0.9060.28Maravai LifeSciences$185.74M6.19-$130.77M-$0.71N/A Do insiders & institutionals hold more shares of KNSA or MRVI? 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer KNSA or MRVI? In the previous week, Kiniksa Pharmaceuticals International and Kiniksa Pharmaceuticals International both had 3 articles in the media. Kiniksa Pharmaceuticals International's average media sentiment score of 1.19 beat Maravai LifeSciences' score of 0.48 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is KNSA or MRVI more profitable? Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Maravai LifeSciences' net margin of -51.07%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Maravai LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals International9.69% 13.26% 9.86% Maravai LifeSciences -51.07%-17.87%-9.08% SummaryKiniksa Pharmaceuticals International beats Maravai LifeSciences on 12 of the 15 factors compared between the two stocks. Get Maravai LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRVI vs. The Competition ExportMetricMaravai LifeSciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.15B$8.28B$6.33B$12.33BDividend YieldN/A2.52%2.80%5.36%P/E Ratio-6.2716.2320.8825.51Price / Sales6.198.61520.5073.06Price / Cash10.0816.9443.1855.00Price / Book3.124.0110.017.03Net Income-$130.77M$224.05M$3.54B$334.92M7 Day Performance3.85%2.51%0.38%-0.40%1 Month Performance21.06%5.45%-0.02%1.07%1 Year Performance98.00%2.00%35.07%34.65% Maravai LifeSciences Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRVIMaravai LifeSciences3.1828 of 5 stars$4.46+0.6%$5.50+23.5%+84.6%$1.15B$185.74MN/A610Positive NewsDNTHDianthus Therapeutics2.5525 of 5 stars$86.60-0.6%$117.82+36.0%+364.3%$4.74B$2.04MN/A80LEGNLegend Biotech4.0229 of 5 stars$25.34-1.0%$58.31+130.1%-6.5%$4.69B$1.03BN/A2,965Analyst ForecastINDVIndivior3.4603 of 5 stars$38.22-1.6%$39.33+2.9%+228.6%$4.66B$1.24B19.591,051NAMSNewAmsterdam Pharma2.0895 of 5 stars$39.02-1.4%$48.00+23.0%+84.8%$4.57B$22.50MN/A4Gap DownHigh Trading Volume Related Companies and Tools Related Companies DNTH Alternatives LEGN Alternatives INDV Alternatives NAMS Alternatives KNSA Alternatives MANE Alternatives AMRX Alternatives TVTX Alternatives CRNX Alternatives CPRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRVI) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
